title: Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
abstract: Lymphokine activated killer (LAK) activity was induced in human peripheral mononuclear blood cells by human recombinant interleukin-2. Monocytes were required for optimal rapid proliferation of cells with LAK activity. They had no influence on the expression of tumoricidal activity by the LAK cells. The effector cells killed K562 erythroleukemia cells and WiDr colon cells differently, i.e. contact areas with WiDr cells were limited, whereas the contact areas between effector cells and K562 cells were much longer. Using mixtures of hot and cold target cells it was shown that effector cells preferably bind with K562 cells, impeding the binding of WiDr cells. Differences in expression of cytotoxicity of LAK cells against WiDr and K562 cells respectively was also observed after culturing the LAK cells for a relatively longer period. Cytotoxicity against WiDr was maximal at 3-16 days after starting LAK cell generation, whereas cytotoxicity against K562 was kept constantly high for at least 21 days. The addition of biological response modifiers [PHA and anti-CD3 antibody (OKT3)] during the LAK cell induction also had different effects on the expression of LAK activity against WiDr and K562 cells. Whereas PHA, in combination with rIL-2 had no significant influence on the cytotoxicity against WiDr cells, the cytotoxicity against K562 was significantly inhibited. Addition of anti-CD3 antibody diminished the cytotoxicity against WiDr target cells and had no influence on the cytotoxicity against K562 cells.
authors.affiliation: Pathologie/AZU, Utrecht, The Netherlands.
authors.forename: H F
authors.initials: HF
authors.lastname: Dullens
authors.forename: J C
authors.initials: JC
authors.lastname: Wind
authors.forename: R A
authors.initials: RA
authors.lastname: Maas
authors.forename: M R
authors.initials: MR
authors.lastname: Bernsen
authors.forename: I M
authors.initials: IM
authors.lastname: Vulto
authors.forename: L H
authors.initials: LH
authors.lastname: Rademakers
authors.forename: W
authors.initials: W
authors.lastname: Den Otter
mesh_terms: D002277:Carcinoma / Q000276:immunology*; D003110:Colonic Neoplasms / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000648:ultrastructure; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008213:Lymphocyte Activation; D008854:Microscopy, Electron; D009000:Monocytes / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D007155:Immunologic Factors; D007376:Interleukin-2